While OSM, LIF, and IL-6 can induce STAT3, AKT, and ERK signaling in breast cancer cells, in the absence of studies using combinations of STAT3, AKT, and ERK inhibitors, it is difficult to determine which is the dominant downstream mediator. The gene discussed is STAT3; the disease is breast carcinoma.